UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 24, 2014
Ohr Pharmaceutical,
Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
333-88480 |
#46-5622433 |
| (State or other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
|
800 Third Avenue, 11th Floor, New York, NY |
10022 |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: (212)-682-8452
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01. Regulation FD.
On June 24, 2014, at 8:30 a.m. (Eastern Time), Ohr Pharmaceutical, Inc. (the “Company”) held a live teleconference call and webcast to provide additional information on the interim clinical trial results of a Phase II clinical trial of Squalamine eye drops in patients with wet age-related macular degeneration. As a supplement to the teleconference call and webcast, the Company provided a slide presentation, a copy of which is attached to this Current Report on Form 8-K as exhibit 99.1. The slide presentation will also be available at www.ohrpharmaceutical.com.
The information contained herein is being furnished pursuant to Item 7.01 of Form 8-K, “Regulation FD Disclosure.” This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 8.01. Other Events.
On June 24, 2014, the Company issued a press release announcing interim results of a Phase II clinical trial of Squalamine eye drops in patients with wet age-related macular degeneration. A copy of the press release is being furnished as exhibit 99.2 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
|
Number |
Description |
| Exhibit 99.1 | Slide deck for Ohr Pharmaceutical, Inc. teleconference call and webcast presentation on June 24, 2014. |
| Exhibit 99.2 | Press release dated June 24, 2014 |
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| OHR PHARMACEUTICAL, INC.
| ||
| By: | /s/ Irach Taraporewala | |
| Dr. Irach Taraporewala, President and CEO | ||
| Date: | June 24, 2014 | |
| 3 |